Symphony CLO IV Ltd. Ratings Raised On Five Class Dec 11

  • ID: 2034906
  • December 2011
  • Standard & Poors
1 of 3

OVERVIEW We raised our ratings on the class A, B, C, D, and E notes issued by Symphony CLO IV Ltd. and removed them from CreditWatch with positive implications. The upgrades reflect improved performance we have observed in the deal's underlying asset portfolio since we lowered our ratings on the transaction on Oct. 23, 2009. NEW YORK (Standard & Poor's) Dec. 27, 2011--Standard & Poor's Ratings Services today raised its ratings on the class A, B, C, D, and E notes from Symphony CLO IV Ltd., a U.S. collateralized loan obligation (CLO) transaction managed by Symphony Asset Management LLC. At the same time, we removed our ratings on the upgraded notes from CreditWatch, where we placed them with positive implications...

Companies mentioned in this report are: Symphony CLO IV Ltd
Action: Removed From CreditWatch
Action: Upgraded

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

Symphony CLO IV Ltd

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our


Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.